LOCUST WALK WEBINARS & PODCASTS
Biotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma Transactions
Click Here for a full summary of the episode. During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
Biotalk Episode 14: A Conversation with Kendalle Burlin O’Connell of MassBio
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk’s Geoff Meyerson welcomes Kendalle Burlin O’Connell, Esq., CEO and President of MassBio, the nation’s pioneering biotechnology trade association, which plays a pivotal role in representing and supporting the vibrant Massachusetts life sciences industry.
Biotalk Episode 13: 2023 Year-In-Review Report: Global Trends in Biopharma Transactions
Click Here for a full summary of the episode. During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
Biotalk Episode 12: A Conversation with Soufiane Aboulhouda of Nucleate
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes with Soufiane Aboulhouda, Co-Founder and Chairman of the Board of Nucleate, a global non-profit dedicated to empowering future biotech leaders through education and fostering innovation in life sciences companies.
Biotalk Episode 11: A Conversation with Shehnaaz Suliman of ReCode Therapeutics
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its selective organ targeting lipid nanoparticle platform to power the next wave of mRNA and gene correction therapeutics.
Biotalk Episode 10: A Conversation with Errik Anderson of Alloy Therapeutics
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Errik Anderson, CEO and Founder of Alloy Therapeutics, to the podcast. Alloy is a trailblazing drug-discovery company, bringing collaborative platforms and services to the biotech world, making cutting-edge biologics accessible to everyone, from academia and small biotechs to major pharmaceutical companies.
Biotalk Episode 9: 2023 Q3 Report: Global Trends in Biopharma Transactions
Click Here for a full summary of the episode. During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets, strategic partnering, and M&A.
Biotalk Episode 8: A Conversation with Helen Ho of Blueprint Medicines
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Andy Meyerson welcomes Helen Ho, Chief Business Officer of Blueprint Medicines, to the podcast. Blueprint Medicines is a pioneering global precision therapy company committed to crafting life-altering medications for individuals with cancer and blood disorders.
Biotalk Episode 7: A Conversation with Howard Federoff of Ryne Biotechnology
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Howard Federoff, MD PhD, Scientific Co-Founder, Chief Medical Officer, and Director of Ryne Biotechnology, to the podcast. Join us as we delve into Ryne Bio’s pioneering work centered on advancing off-the-shelf neuron replacement therapies, poised to revolutionize the treatment landscape for neurological disorders.
Biotalk Episode 6: A Conversation with Jason Kelly of Ginkgo Bioworks
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Andy Meyerson welcomes Jason Kelly, co-Founder and CEO of Ginkgo Bioworks to the podcast. During the episode, Jason delves into Ginkgo’s inception story, the distinctive contours of its business model, its unique role as a Contract Research Organization (CRO), and addresses the paramount challenges currently confronting the biotech industry.
Biotalk Episode 5: A Conversation with Onaiza Cadoret-Manier of Ionis Pharmaceuticals
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Onaiza Cadoret-Manier, Executive Vice President, Chief Global Product Strategy & Operations Officer at Ionis Pharmaceuticals to the podcast. During the episode, Onaiza discusses her journey into biotech, her tenure at Ionis and challenges overcome while shifting from an R&D focus to commercialization, and her perspective and outlook on the biotech market today.
Biotalk Episode 4: 2023 Q2 Report: Global Trends in Biopharma Transactions
Click Here for a full summary of the episode. During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Q2 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets, strategic partnering, and M&A.
Locust Walk RNA Innovation Conference – May 9th, 2023
Locust Walk’s second annual Innovation Conference was a huge success with over 350 attendees. This year’s theme was focused on next generation RNA medicine in partnership with Dr. Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine, and Dr. Phil Zamore, Chair of the UMass Chan RNA Therapeutics Institute. We brought together private companies and full-time researchers on the cutting edge of RNA therapeutics to feature their work for investors, strategic partners, and other academics interested in the latest innovations in RNA as well as their translation to the clinic.
Biotalk Episode 3: 2023 Q1 Report: Global Trends in Biopharma Transactions
Click Here for a full summary of the episode. This episode of Biotalk is focused on Locust Walk’s 2023 First Quarter Market Conditions Report, in which we apply the latest data to analyze current activities in the life sciences deal landscape. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity.
Biotalk Episode 2: A Conversation with Andrew Allen – March 15th, 2023
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk welcomes Andrew Allen, M.D., Ph.D., Co-Founder, President, CEO, and board member of Gritstone Bio to the podcast. Prior to Gritstone, Dr. Allen co-founded Clovis Oncology and served as CMO. He was CMO at Pharmion Corporation and also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company. Dr. Allen discusses the founding of Gritstone bio, it’s evolution since 2015, and the two key aspects to the Gritstone platform.
Biotalk: Expectations for 2023 Biotech Market – February 2nd, 2023
Click Here for a full summary of the episode. Our first Biotalk podcast is focused on Locust Walk’s 2022 year-in-review market conditions, which was released the first day of JPMorgan and rapidly accumulated over 500 downloads. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. We wanted to share some insights into the report and discuss key trends, opportunities and predictions for the industry in 2023.
Navigating the Biopharma Depression: More Pain or 2023 Gain? – October 20th, 2022
Click Here for a full summary of the webinar. The biopharma market has largely remained suppressed as we enter the final leg of what was a painful 2022. Private financings are down 80% and IPOs down 95% in volume since Q3 2021, while the performance of the XBI has dropped ~40% over the last 12 months. With the Federal Reserve continuing to raise interest rates and the looming impact of the Inflation Reduction Act, the macroeconomic headwinds at play bear uncertainty across the Biopharma sector. In this webinar, Locust Walk and other industry leaders exchanged their views on how to navigate this “narrow” depression and what companies can do to successfully make it to the other side.
The State of Biopharma: Navigating a Stormy Climate – July 26th, 2022
Click Here for a full summary of the webinar. The biopharma sector remains full of uncertainty with peak negative sentiment heading into the halfway point of 2022. With the public markets closed for much of the second quarter, companies are seeing the ripple effect of a capital-constrained environment. In this webinar, Locust Walk and other industry leaders exchanged their views on navigating the current state of biopharma and positioning for a successful future.
Biotech Is Down But Not Out: Developing A Game Plan In A Volatile Market – April 27th, 2022
Click Here for a full summary of the webinar. The seas have remained choppy for the biopharma industry in the early part of 2022. With a bearish capital-raising environment and unaligned valuations to keep deal makers treading water, how biotech’s will remain afloat has become the crux of the sector. In this webinar, Locust Walk and other leading experts in strategic dealmaking and finance discuss the current state of biopharma and what to expect as we settle into 2022.
Locust Walk Stem Cell Tx Conference in partnership with Harvard Stem Cell Institute – April 11th, 2022
We are excited to announce we held our first Locust Walk Stem Cell Tx Conference in partnership with Harvard Stem Cell Institute! We put on what we believe is a first of its kind event that combines the best of an investment banking conference with investors, partnering conference with strategic partners, and academic conference where cutting-edge research is presented. After our experience co-founding Garuda Therapeutics last fall and launching with a $72M Series A, Locust Walk is all in on stem cell therapeutics companies. We believe that more attention needs to be paid to this important and growing field of research that has the potential to improve human health in almost every disease area.
2022 Biopharma Capital Outlook: Strategies to Navigate a Shifting Financing & Strategic Marketplace – January 27th, 2022
Click Here for a full summary of the webinar. The biopharma public markets faced significant headwinds in 2021, as major indices in the sector underperformed dramatically relative to the broader market. What drove such a significant downturn? When and how will it bounce back? What strategic shifts will we see innovators employ to recoup and reinforce their value? Locust Walk held a webinar with a few of the industry’s leading experts in corporate dealmaking and investing to discuss the present and future state of biopharma.
Has Biotech Peaked? – November 16th, 2021
On the heels of the publication of Locust Walk’s latest Quarterly Market Conditions Report, we are joined by a great panel of experts to help us unpack the trends in the industry as Q3 ended.
Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals – September 30th, 2021
On the heels of the publication of Locust Walk’s latest white paper “Bought Not Sold” we are joined by a great panel of experts to help us unpack how M&A transactions evolve in the biopharma space.
What Biopharma Should Expect From The Public Markets In 2H 2021 – August 11, 2021
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2021 Q2 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape. For this quarter’s webinar, executives from across the biopharma sector will share their market forecasts for the second half of 2021.
The Evolving Role of Crossover Financing – May 20, 2021
On the heels of the publication of Locust Walk’s white paper “Crossover Evolution: The Evolving Role of the Crossover Financing Round” join us for a live webinar discussion.
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived. That was temporary. Biotech had a record-setting performance for the remainder of the year, when it led the bull market to record highs and unprecedented fundraising. Crossover financing rounds were a leading trend in that recovery.
Should Biotech Bother With Early-Stage Collaborations Given the Hot Financing Market? – May 5, 2021
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape. For this quarter’s webinar, we’ll be discussing the nuances of early-stage collaborations relative to recent dealflow.
The Future of Biotech Financing: Continued Boom or Bust? – December 3, 2020
Considering the financing landscape for biopharma companies continues to be robust, a big question remains, which is ‘how long can we trust this trend?’ While predicting the future isn’t realistic, we brought together a handful of panelists to discuss current biopharma financing trends and share things to consider while you’re mapping out your strategy for 2021 and beyond.
Knocking At The Door: Challenges Women Face With Biopharma Boards – September 23, 2020
Though there’s no shortage of female-led biotech companies, women still make up less than 20% of biotech boards. Often times women are asked “have you been on a board before?” But how do women get that initial experience into the “club” when they continue to face roadblocks?
Brave New World: Challenges from the East, Asia Biopharma, and Response to COVID-19 – July 1, 2020
Please join Hayato Watanabe, SVP, Head of Asia at Locust Walk, Ken Araki, Corporate Officer, Head of Global Business Development at Santen Pharmaceutical Co., Ltd, Sean Cao, Managing Director, CBC Group, and Wendy Pan, Partner, Technology & Life Sciences Group, Goodwin.
Accessing Capital in the time of COVID: Challenges, Opportunities, and Best Practices – June 11, 2020
Join Brian Coleman, Managing Director, Global Head of Capital Markets & Sales, Geoff Meyerson, CEO & Co-Founder of Locust Walk, Gregg Beloff, Managing Director of Danforth Advisors, and William Hicks, Partner at Mintz Levin to talk about how biopharma companies can get access to capital in this time. You don’t want to miss this one!
Biopharma Deal Makers Approach to Maximizing Strategic Partnerships – May 7, 2020
Join Geoff Meyerson, CEO & Co-Founder of Locust Walk, Chris Ehrlich, Senior Managing Director, Global Head of Strategic Partnerships at Locust Walk, Sara Solomon, Partner, Goodwin, and Malcolm Bates, Partner, Goodwin discuss strategies for maximizing strategic partnerships, especially in the time of COVID-19.
Q1 2020 Biopharma Market Conditions Report Live Panel – April 16, 2020
Join Geoff Meyerson, CEO & Co-Founder of Locust Walk, Chris Ehrlich, Senior Managing Director, Global Head of Strategic Partnerships at Locust Walk, and Barbara Cooley, Partner, International Head of Life Science Practice at Cooley to hear their insights on Q1 2020 biopharma trends and get an insight into what’s ahead for 2020.
Strategic Implications of COVID-19 on Biopharma – March 31, 2020
Join Geoff Meyerson, CEO & Co-Founder of Locust Walk, Chris Ehrlich, Senior Managing Director, Global Head of Biopharma at Locust Walk, Brian Coleman, Managing Director, Global Head of Financing and Sales, along with Tim Ehrlich, Partner at Gunderson Dettmer to discuss the strategic implications COVID-19 is having on biopharma companies and investors.
Fundamentals and Recent Trends in Life Sciences Private Financing – March 15, 2018
Locust Walk has prepared this webinar in collaboration with T1D Exchange, a nonprofit whose mission is to accelerate new therapies and improve care for people affected by type 1 diabetes. This webinar is for anyone who is seeking to raise a private financing round.
BioPharma Partnering in Japan – December 18, 2017
This half an hour webinar will provide valuable education and insights into the best practices of life science deal-making based on Locust Walk’s transaction advisory experience.
Life Science Financing Term Sheet Review- October 17, 2017
The webinar will be a comprehensive overview of each section of a private financing term sheet. The content is geared towards life science senior executives and business development professionals who may be intimidated by and/or are interested in learning more about each of the sections of a term sheet and the purpose for its inclusion. Potential pitfalls of key terms will also be discussed.
BioPharma Sell-Side Deal Process Keys to Success – May 3, 2017
Webinar provides valuable education and insights into the best practices of life science deal-making based on Locust Walk’s transaction advisory experience.
BioPharma Buy-Side Deal Process Keys to Success- June 13, 2017
The session includes insights & techniques that will be interesting not only to potential buyers, but also to those on the sell-side looking to gain a greater understanding of the buy-side mentality.
Fundamentals and Key Trends in Life Sciences Private Financing- July 26, 2017
Webinar covers key issues surrounding the fundamentals of and insights into how best to finance private biotechnology companies in today’s competitive and evolving marketplace. The session will also include an update on recent trends in the private financing market.
BioPharma Valuation Analysis- September 19, 2017
The webinar covers key issues surrounding how to best value a biopharma company. The content is geared towards life science senior executives and business development professionals who are interested in learning more about or improving their skills in valuation analysis.